Sign Out
VASCEPA (icosapent ethyl) is indicated to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to: established cardiovascular disease; or diabetes, and at least one other cardiovascular risk factor.
Pediatrics (<18 years): No data are available; therefore, an indication for pediatric use has not been authorized.
Geriatrics (≥65 years): Evidence from clinical studies and experience suggests that use in the geriatric population is not associated with differences in safety or effectiveness, but greater sensitivity of some older individuals cannot be ruled out.
